

Rebiotix, a Ferring company, completes enrollment for phase 3 clinical trial of microbiota-based RBX2660

This article was originally published [here](#)

The Centers for Disease Control and Prevention (CDC) has classified C. diff as an urgent public health threat, with limited options for treatment. RBX2660 was developed under Rebiotix's

The post [Rebiotix, a Ferring company, completes enrollment for phase 3 clinical trial of microbiota-based RBX2660](#) appeared first on [Pharmaceutical Business review](#).